Evotec: Milestone as part of its discovery alliance with Boehringer Ingelheim

16-Oct-2013 - Germany

Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of EUR 4.0 m to Evotec. The milestone was for the transition of an oncology molecule into pre-clinical development.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'This is the twentieth milestone achieved as part of our alliance with Boehringer Ingelheim and represents a second oncology compound transitioning into pre-clinical development. I would like to congratulate the teams from both companies on their continuing excellent progress in the collaboration.'

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance